Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment

Diabetologia

Volumn 48, Issue 6, 2005, Pages 1105-1113

  De Vries, R ^a   Kerstens, M N ^a   Sluiter, W J ^a   Groen, A K ^b   Van Tol, A ^a,c   Dullaart, R P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cellular cholesterol efflux; High density lipoprotein; Lipid transfer; Simvastatin; Type 1 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; PHOSPHOLIPID TRANSFER PROTEIN; PLACEBO; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CELL LINE; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FIBROBLAST; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; BIOLOGICAL TRANSPORT; CELLS, CULTURED; CHOLESTEROL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FIBROBLASTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PHOSPHOLIPIDS; REFERENCE VALUES; SIMVASTATIN; TRIGLYCERIDES;

EID: 21344441468     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1760-0     Document Type: Article

References (54)

1. Tall AR (1990) Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 86:379-384
2. Fielding CJ, Fielding PE (1995) Molecular physiology of reverse cholesterol transport. J Lipid Res 36:211-228
3. Barter PJ, Rye KA (1993) High density lipoproteins and reverse cholesterol transport. Curr Opin Lipidol 4:210-217
4. Bruce C, Tall AR (1995) Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Curr Opin Lipidol 6:311
5. Eisenberg S (1984) High density lipoprotein metabolism. J Lipid Res 25:1017-1058
6. Castro GR, Fielding CJ (1988) Early incorporation of cell-derived cholesterol into pre-β-migrating high-density lipoprotein. Biochemistry 27:25-29
7. Von Eckardstein A, Huang Y, Assmann G (1994) Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 5:404-416
8. Borggreve SE, De Vries R, Dullaart RPF (2003) Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 33:1051-1069
9. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, Van Tol A, Ehnholm C (1993) Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 268:4032-4036
10. Von Eckardstein A, Jauhiainen M, Huang Y et al (1996) Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre β1-HDL. Biochim Biophys Acta 1301:255-262
11. Rye KA, Clay MA, Barter PJ (1999) Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 145:227-238
12. Krolewski AS, Kosinski EJ, Warram JH et al (1987) Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59:750-755
13. Colhoun HM, Scheek LM, Rubens MB et al (2001) Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. Diabetes 50:652-659
14. Colhoun HM, Taskinen MR, Otvos JD, Van Den Berg P, O'Connor J, Van Tol A (2002) Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 51:3300-3305
15. Dullaart RPF (1995) Plasma lipoprotein abnormalities in type 1 (insulin-dependent) diabetes mellitus. Neth J Med 46:44-54
16. Duell PB, Oram JF, Bierman EL (1991) Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 40:377-384
17. Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin en fluvastatin in patients with hypercholesteremia (the CURVES study). Am J Cardiol 81:582-587
18. Rustemeijer C, Schouten JA, Janssens ENW, Spooren PFMJ, Van Doormaal JJ (1997) Pravastatin in diabetes-associated hypercholesterolemia. Acta Diabetol 34:294-300
19. Herd JA, Ballantyne CM, Farmer JA et al (1997) Effects of fluvastatine on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 80:278-286
20. 4S Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
21. Plehn JF, Davis BR, Sacks FM et al (1999) Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care investigators. Circulation 99:216-223
22. Downs LR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 279:1615-1622
23. Ahnadi CE, Berthezène F, Ponsin G (1993) Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis 99:219-228
24. Schaefer JR, Schweer H, Ikewaki K et al (1999) Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 144:177-184
25. Dullaart RPF, Riemens SC, Scheek LM, Van Tol A (1999) Insulin decreases plasma cholesteryl ester transport but not cholesterol esterification in healthy subjects as well as in normotriglyceridemic patients type 2 diabetes. Eur J Clin Invest 29:663-671
26. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499-552
27. Dullaart RPF, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A (1994) Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 24:188-194
28. Speijer H, Groener JE, Van Ramshorst E, Van Tol A (1991) Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 90:159-168
29. Groener JE, Pelton RW, Kostner GM (1986) Improved estimation of cholesteryl ester transfer/exchange activity in serum or plasma. Clin Chem 32:283-286
30. Van Kaperen R, Van Tol A, Vermeulen P et al (2000) Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 20:1082-1088
31. Brussaard JH, Dallinga-Thie GM, Groot PHE, Katan MB (1980) Effects of amount and type of dietary fat on serum lipids, lipoproteins and apolipoproteins in man. A controlled 8-week trial. Atherosclerosis 36:515-527
32. Hovingh GK, Wijland MJ, Brownlie A et al (2003) The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia. J Lipid Res 44:1251-1255
33. De La Llera-Moya M, Atger V, Paul JL et al (1994) A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb 14:1056-1065
34. Smith PK, Krohn RI, Hermanson GT et al (1985) Measurement of protein using bicinchoninic acid. Ann Biochem 150:76-85
35. Dullaart RPF, Van Tol A (2001) Twenty four hour insulin infusion impairs the ability of plasma from healthy subjects and type 2 diabetic patients to promote cellular cholesterol efflux. Atherosclerosis 157:49-56
36. Rye KA, Jensen G, Barter PJ, Ehnholm C (1998) Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. J Lipid Res 39:613-622
37. Mann CJ, Yen FT, Grant AM, Bihain BE (1991) Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 88:2059-2066
38. Tato F, Vega F, Tall AR, Grundy SM (1995) Relation between cholesterol transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol 15:112-120
39. Rothblat GH, De La Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, Phillips MC (1999) Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 40:781-796
40. Yancey PG, Bortnick AE, Kellner-Weibel G, De La Llera-Moya M, Phillips MC, Rothblat GH (2003) Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23:712-719
41. Fielding CJ, Bist A, Fielding PE (1999) Intracellular cholesterol transport in synchronized human skin fibroblasts. Biochemistry 38:2506-2513
42. Denis M, Bissonnette R, Haidar B, Krimbou L, Bouvier M, Genest J (2003) Expression, regulation, and activity of ABCA1 in human cell lines. Mol Genet Metab 78:265-274
43. Wang N, Lan D, Chen W, Matsuura F, Tall AR (2004) ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 101:9774-9779
44. Fournier N, Paul JL, Atger V et al (1997) HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol 17:2685-2691
45. Favari E, Lee M, Calabresi L, Franceschini G, Zimetti F, Kovanen PT (2004) Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1 - but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J Biol Chem 279:9930-9936
46. Oram J, Wolfbauer G, Vecchio G, Albers JJ (2003) Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J Biol Chem 26:52379-52385
47. Igau B, Castro G, Clavey V et al (1997) In vivo glycosylated LpA-I subfraction. Evidence for structural and functional alterations. Arterioscler Thromb Vasc Biol 17:2830-2836
48. Passarelli M, Shimabukuro AFM, Catanozi S et al (2000) Diminished rate of mouse peritoneal macrophage cholesterol efflux is not related to the degree of HDL glycation in diabetes mellitus. Clin Chim Acta 301:119-134
49. Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV (2000) Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 49:167-177
50. Guérin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ (2000) Action of atorvastatin in combined hyperlipidemia. Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20:189-197
51. Guérin M, Egger P, Soudant C et al (2002) Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163:287-296
52. Soedamah-Muthu SS, Colhoun HM, Thomason MJ et al (2003) The effects of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 167:243-255
53. Wolfrum S, Jensen KS, Liao JK (2003) Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 23:729-736
54. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, Von Eckardstein A (2002) HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161:1-16